BACKGROUND: The EphB2 gene was recently implicated as a prostate cancer (PC) tumour suppressor gene, with somatic inactivating mutations occurring in approximately 10% of sporadic tumours. We evaluated the contribution of EphB2 to inherited PC susceptibility in African Americans (AA) by screening the gene for germline polymorphisms. METHODS: Direct sequencing of the coding region of EphB2 was performed on 72 probands from the African American Hereditary Prostate Cancer Study (AAHPC). A case-control association analysis was then carried out using the AAHPC probands and an additional 183 cases of sporadic PC compared with 329 healthy AA male controls. In addition, we performed an ancestry adjusted association study where we adjusted for individual ancestry among all subjects, in order to rule out a spurious association due to population stratification. RESULTS: Ten coding sequence variants were identified, including the K1019X (3055A-->T) nonsense mutation which was present in 15.3% of the AAHPC probands but only 1.7% of 231 European American (EA) control samples. We observed that the 3055A-->T mutation significantly increased risk for prostate cancer over twofold (Fisher's two sided test, p = 0.003). The T allele was significantly more common among AAHPC probands (15.3%) than among healthy AA male controls (5.2%) (odds ratio 3.31; 95% confidence interval 1.5 to 7.4; p = 0.008). The ancestry adjusted analyses confirmed the association. CONCLUSIONS: Our data show that the K1019X mutation in the EphB2 gene differs in frequency between AA and EA, is associated with increased risk for PC in AA men with a positive family history, and may be an important genetic risk factor for prostate cancer in AA.
BACKGROUND: The EphB2 gene was recently implicated as a prostate cancer (PC) tumour suppressor gene, with somatic inactivating mutations occurring in approximately 10% of sporadic tumours. We evaluated the contribution of EphB2 to inherited PC susceptibility in African Americans (AA) by screening the gene for germline polymorphisms. METHODS: Direct sequencing of the coding region of EphB2 was performed on 72 probands from the African American Hereditary Prostate Cancer Study (AAHPC). A case-control association analysis was then carried out using the AAHPC probands and an additional 183 cases of sporadic PC compared with 329 healthy AA male controls. In addition, we performed an ancestry adjusted association study where we adjusted for individual ancestry among all subjects, in order to rule out a spurious association due to population stratification. RESULTS: Ten coding sequence variants were identified, including the K1019X (3055A-->T) nonsense mutation which was present in 15.3% of the AAHPC probands but only 1.7% of 231 European American (EA) control samples. We observed that the 3055A-->T mutation significantly increased risk for prostate cancer over twofold (Fisher's two sided test, p = 0.003). The T allele was significantly more common among AAHPC probands (15.3%) than among healthy AA male controls (5.2%) (odds ratio 3.31; 95% confidence interval 1.5 to 7.4; p = 0.008). The ancestry adjusted analyses confirmed the association. CONCLUSIONS: Our data show that the K1019X mutation in the EphB2 gene differs in frequency between AA and EA, is associated with increased risk for PC in AA men with a positive family history, and may be an important genetic risk factor for prostate cancer in AA.
Authors: C M Zeigler-Johnson; A H Walker; B Mancke; E Spangler; M Jalloh; S McBride; A Deitz; S B Malkowicz; D Ofori-Adjei; S M Gueye; T R Rebbeck Journal: Hum Hered Date: 2002 Impact factor: 0.444
Authors: Clive J Hoggart; Eteban J Parra; Mark D Shriver; Carolina Bonilla; Rick A Kittles; David G Clayton; Paul M McKeigue Journal: Am J Hum Genet Date: 2003-06 Impact factor: 11.025
Authors: Glenn R Cunningham; Carol M Ashton; John F Annegers; Julianne Souchek; Marcella Klima; Brian Miles Journal: Prostate Date: 2003-09-01 Impact factor: 4.104
Authors: Rick A Kittles; Weidong Chen; Ramesh K Panguluri; Chiledum Ahaghotu; Aaron Jackson; Clement A Adebamowo; Robin Griffin; Tyisha Williams; Flora Ukoli; Lucile Adams-Campbell; John Kwagyan; William Isaacs; Vincent Freeman; Georgia M Dunston Journal: Hum Genet Date: 2002-05-07 Impact factor: 4.132
Authors: Graham Casey; Phillippa J Neville; Sarah J Plummer; Ying Xiang; Lisa M Krumroy; Eric A Klein; William J Catalona; Nina Nupponen; John D Carpten; Jeffrey M Trent; Robert H Silverman; John S Witte Journal: Nat Genet Date: 2002-11-04 Impact factor: 38.330
Authors: David C Miller; S Lilly Zheng; Rodney L Dunn; Aruna V Sarma; James E Montie; Ethan M Lange; Deborah A Meyers; Jianfeng Xu; Kathleen A Cooney Journal: Cancer Res Date: 2003-07-01 Impact factor: 12.701
Authors: Janet L Stanford; Leah P Sabacan; Elizabeth A Noonan; Lori Iwasaki; Jianfen Shu; Ziding Feng; Elaine A Ostrander Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-09 Impact factor: 4.254
Authors: Jill E Chrencik; Alexei Brooun; Michael I Recht; George Nicola; Leila K Davis; Ruben Abagyan; Hans Widmer; Elena B Pasquale; Peter Kuhn Journal: J Biol Chem Date: 2007-09-26 Impact factor: 5.157
Authors: L J Ricks-Santi; V Apprey; T Mason; B Wilson; M Abbas; W Hernandez; S Hooker; M Doura; G Bonney; G Dunston; R Kittles; C Ahaghotu Journal: Prostate Cancer Prostatic Dis Date: 2012-07-17 Impact factor: 5.554
Authors: Christiane M Robbins; Wenndy Hernandez; Chiledum Ahaghotu; James Bennett; Gerald Hoke; Terry Mason; Curtis A Pettaway; Srinivasan Vijayakumar; Sally Weinrich; Paulette Furbert-Harris; Georgia Dunston; Isaac J Powell; John D Carpten; Rick A Kittles Journal: Prostate Date: 2008-12-01 Impact factor: 4.104